Pfizer Faces Key R&D Challenges as Chief Scientific Officer Mikael Dolsten Departs

1. Mikael Dolsten's Departure: Pfizer's Chief Scientific Officer and President, Pfizer Research & Development, Dr. Mikael Dolsten, will depart the company after a 15-year tenure, with a successor search process expected to last several months.
2. R&D Achievements: Under Dolsten's leadership, Pfizer received over 35 drug and vaccine approvals, including the COVID-19 vaccine and oral therapeutic.
3. Six Key R&D Questions: The company faces significant R&D challenges, including the future of its COVID-19 vaccine business, pipeline development, and the impact of Dolsten's departure on the company's scientific direction.
4. Successor